Alkermes plc (NASDAQ:ALKS) is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter revenue of $ 238.39 million.
Looking ahead, the full year income are expected at $ 0.10 per share on the revenues of $ 982.45 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 965.00 million ~ $ 1,005.00 million, where as bottomline are predicted in a range of $ 0.25 ~ $ 0.43 per share
Click Here For More Historical Outlooks Of Alkermes plc
Previous Quarter Performance
Alkermes plc reported income for the second quarter of $ 0.06 per share, from the revenue of $ 247.53 million. The quarterly earnings fell 33.33 percent while revenues dropped 11.56 percent compared with the same quarter last year. The top line results outshined analysts by $ 14.78 million or 6.35 percent.
Stock Performance
Shares of Alkermes plc traded low $ -0.52 or -3.27 percent on Wednesday, reaching $ 15.39 with volume of 1.07 million shares. Alkermes plc has traded high as $ 15.73 and has cracked $ 15.35 on the downward trend
According to the previous trading day, closing price of $ 15.39, representing a 32.80 % increase from the 52 week low of $ 11.98 and a 27.29 % decrease over the 52 week high of $ 21.88.
The company has a market capital of $ 2.45 billion and is part of the Healthcare sector and Drug Delivery industry.
Conference Call
Alkermes plc will be hosting a conference call at 8:00 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.alkermes.com
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The companys marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders.
